RISK MANAGEMENT OF PRESCRIPTION AND PREPARATION OF CYTOTOXIC DRUGS IN HOSPITAL PHARMACIES
PS-121
MODEL FOR ADVISING ON INTERACTIONS AND ADVERSE REACTIONS OF TYROSINE KINASE INHIBITOR TREATMENT
PS-120
CHALLENGES IN EVALUATION OF ELECTRONIC SWITCH MODULES FOR HOME TREATMENT
PS-119
Effect of anticoagulation and antiplatelet therapy on the incidence of intracranial bleeding after thrombolysis in patients with acute ischaemic stroke – a pharmacoepidemiological approach
PS-117
DATA QUALITY ANALYSIS OF ADVERSE DRUG EVENTS IN A VOLUNTARY REPORTING SYSTEM
PS-113
BIOLOGICAL TREATMENT ALERTS PROJECT IN RHEUMATOLOGY PATIENTS' ELECTRONIC RECORDS
PS-112
PHARMACEUTICAL ANALYSIS OF ASSISTANCE ON RECONCILIATION OF PEDIATRIC MEDICINES
PS-111
EVALUATION OF THE MEDICINES RECONCILIATION AND VTE RISK ASSESSMENT ROLES OF THE PRESCRIBING PHARMACISTS ON THE ELECTIVE THEATRE ADMISSIONS UNIT
PS-110
EXTENT AND DIVERSITY OF DAY-TO-DAY CLINICAL PHARMACISTS' INTERVENTIONS IN HOSPITALS
PS-109
BARRIERS AND FACILITATORS TO IMPLEMENTING DRUG CHANGES CAUSED BY DRUG TENDERS AND SHORTAGES
PS-108
STUDY OF POTENTIAL DRUG INTERACTIONS WITH ORAL ANTINEOPLASTIC AGENTS IN AN ONCOLOGY OUTPATIENT CLINIC.
PS-106
Administration mistakes in cytostatic unit
PS-105
IMPLEMENTATION OF A UNIQUE AUTOMATION AND MANAGEMENT PLATFORM TO EXTEND PROCESS CONTROL TO ALL MEDICINAL PRODUCTS PREPARED FOR CANCER PATIENTS
PS-104
INITIATIVE FOR IMPROVING MEDICINES SAFETY IN SURGICAL INPATIENTS
PS-103
PRESCRIPTION OF QUETIAPINE FROM THE PERSPECTIVE OF PATIENT SAFETY
